Table 1 Description of populations’ features
Controls (N=20) | Schizoprenia (N=20) | Bipolar disorder (N=20) | P | |
|---|---|---|---|---|
Years | 36.6±7.69 | 39.75±7.86 | 42.45±6.58 | 0.051 |
Females/males | 11/9 | 6/14 | 13/7 | 0.074 |
Ethnic group | Caucasian | Caucasian | Caucasian | |
Smoking (n/y) | 17/3 | 11/9 | 8/11 | 0.018 |
BMI | 23.66±3.13 | 26.85±6.20 | 26.85±4.15 | 0.054 |
Age of onset | — | 25.45±6.57 | 27.44±6.13 | 0.318 |
Length of illness (years) | — | 14.7±9.4 | 14.56±6.43 | 0.714 |
Hospitalizations (n) | — | 3.75±5.56 | 5.32±7.07 | 0.557 |
Chlorpromazine equivalent | — | 237.04 | 50.5 | 0.002 |
Antipsychotic lifetime (years) | — | 10.42±8.36 | 5.91±7.03 | 0.061 |
Mood stabilizer lifetime (years) | — | — | 8.54±5.21 | |
GAF | 82.25±4.85 | 45±11.49 | 58.79±13.67 | 0.0001 |
BPRS | ||||
Total | — | 45.83±12.03 | 32.22±5.83 | 0.006 |
Anxiety and depression | — | 11.93±5.12 | 11±4.00 | 0.813 |
Negative symptoms | — | 12.7±4.82 | 7.44±0.73 | 0.0005 |
Positive symptoms | — | 12.75±6.07 | 8.4±6.35 | 0.026 |
Mania | — | 12.75±3.99 | 10.22±1.99 | 0.077 |
BRMRS | — | — | 2.95±5.2 | |
HDRS (21 items) | — | — | 14.21±11.78 |
